RS51320B - Derivati imidazohinolina kao veznici a3 receptora adenozina - Google Patents

Derivati imidazohinolina kao veznici a3 receptora adenozina

Info

Publication number: RS51320B
Authority: RS; Serbia
Prior art keywords: group; branched; straight; atom; zero
Prior art date: 2002-11-15

Application number

YUP-2005/0364A

Other languages

English (en)

Inventor

Sándor BÁTORI

Kinga Boér

Zoltán Kapui

Endre Mikus

Erzsébet WALCZ

Mária BALOGH

Judit VARGÁNÉ SZEREDI

Lajos T. Nagy

Katalin Gerber

Katalin URBÁN-SZABÓ

Peter ARÁNYI

Lászlò BALÁZS

Géza TÍMÁRI

Original Assignee

Sanofi-Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-15

Filing date

2003-11-11

Publication date

2010-12-31

2003-11-11 Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis

2003-11-11 Priority to MEP-190/08A priority Critical patent/MEP19008A/xx

2007-08-03 Publication of RS20050364A publication Critical patent/RS20050364A/sr

2010-12-31 Publication of RS51320B publication Critical patent/RS51320B/sr

Links

RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
102000008161 Adenosine A3 Receptor Human genes 0.000 title 1
108010060261 Adenosine A3 Receptor Proteins 0.000 title 1
239000003446 ligand Substances 0.000 title 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
125000005843 halogen group Chemical group 0.000 abstract 3
125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
125000004430 oxygen atom Chemical group O* 0.000 abstract 3
229910052717 sulfur Inorganic materials 0.000 abstract 3
125000004434 sulfur atom Chemical group 0.000 abstract 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
-1 methylenedioxy group Chemical group 0.000 abstract 2
229910052757 nitrogen Inorganic materials 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Epidemiology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)

YUP-2005/0364A 2002-11-15 2003-11-11 Derivati imidazohinolina kao veznici a3 receptora adenozina RS51320B (sr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
MEP-190/08A MEP19008A (en)	2002-11-15	2003-11-11	Imidazoquinoline derivatives as adenosine a3 receptor ligands

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0203976A HUP0203976A3 (en)	2002-11-15	2002-11-15	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
PCT/HU2003/000095 WO2004046146A1 (en)	2002-11-15	2003-11-11	Imidazoquinoline derivatives as adenosine a3 receptor ligands

Publications (2)

Publication Number	Publication Date
RS20050364A RS20050364A (en)	2007-08-03
RS51320B true RS51320B (sr)	2010-12-31

Family

ID=90001561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
YUP-2005/0364A RS51320B (sr)	2002-11-15	2003-11-11	Derivati imidazohinolina kao veznici a3 receptora adenozina

Country Status (35)

Country	Link
US (2)	US7419977B2 (sr)
EP (1)	EP1560828B9 (sr)
JP (1)	JP4533148B2 (sr)
KR (1)	KR20050088291A (sr)
CN (1)	CN1332960C (sr)
AR (1)	AR041968A1 (sr)
AT (1)	ATE325123T1 (sr)
AU (1)	AU2003282263B2 (sr)
BR (1)	BR0316355A (sr)
CA (1)	CA2505910C (sr)
CO (1)	CO5690577A2 (sr)
CY (1)	CY1105180T1 (sr)
DE (1)	DE60305058T2 (sr)
DK (1)	DK1560828T3 (sr)
EA (1)	EA007595B1 (sr)
ES (1)	ES2263039T3 (sr)
HK (1)	HK1077819A1 (sr)
HR (1)	HRP20050540A2 (sr)
HU (1)	HUP0203976A3 (sr)
IL (1)	IL168516A (sr)
IS (1)	IS2456B (sr)
MA (1)	MA27501A1 (sr)
ME (1)	MEP19008A (sr)
MX (1)	MXPA05005198A (sr)
NO (1)	NO20052866D0 (sr)
NZ (1)	NZ540029A (sr)
PL (1)	PL376837A1 (sr)
PT (1)	PT1560828E (sr)
RS (1)	RS51320B (sr)
SI (1)	SI1560828T1 (sr)
TN (1)	TNSN05133A1 (sr)
TW (1)	TWI248934B (sr)
UA (1)	UA78889C2 (sr)
WO (1)	WO2004046146A1 (sr)
ZA (1)	ZA200503807B (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0105406A3 (en) *	2001-12-21	2003-12-29	Sanofi Aventis	Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) *	2004-04-19	2006-02-28	Sanofi Aventis	Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
US20090088403A1 (en) *	2007-05-07	2009-04-02	Randy Blakely	A3 adenosine receptors as targets for the modulation of central serotonergic signaling
HUP0700395A2 (en) *	2007-06-07	2009-03-02	Sanofi Aventis	Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
EP2456419B1 (en)	2009-07-21	2016-11-23	Oradin Pharmaceutical Ltd.	A3 adenosine receptor ligands for modulation of pigmentation
EP3632426A1 (en)	2013-02-01	2020-04-08	Wellstat Therapeutics Corporation	Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
KR101820909B1 (ko) *	2017-07-07	2018-01-23	퓨쳐메디신 주식회사	아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물
DK3681885T3 (da)	2017-09-15	2024-04-15	Forma Therapeutics Inc	Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer
CN116178369A (zh)	2018-06-29	2023-05-30	福马疗法公司	抑制creb结合蛋白(cbp)
CN113874017A (zh) *	2019-03-15	2021-12-31	福马治疗股份有限公司	抑制环amp-应答元件结合蛋白(creb)
US11795168B2 (en)	2020-09-23	2023-10-24	Forma Therapeutics, Inc.	Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en)	2020-09-23	2023-10-31	Forma Therapeutics, Inc.	Bromodomain inhibitors for androgen receptor-driven cancers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4075343A (en) *	1976-09-13	1978-02-21	Pfizer Inc.	Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
GB1596652A (en) *	1977-01-20	1981-08-26	Roussel Lab Ltd	Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives
IL59104A (en) *	1979-02-09	1984-02-29	Roussel Uclaf	Heterotricyclic derivatives,process for their preparation and pharmaceutical compositions incorporating them
US4644002A (en) *	1979-02-09	1987-02-17	Roussel Uclaf	Imidazo[2,1-C]quinolines, useful as antiallergic agents
FR2448541A1 (fr) *	1979-02-09	1980-09-05	Roussel Uclaf	Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
AU4980999A (en) *	1998-07-10	2000-02-01	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	A3 adenosine receptor antagonists
US6448253B1 (en) *	1998-09-16	2002-09-10	King Pharmaceuticals Research And Development, Inc.	Adenosine A3 receptor modulators
DE60010311T2 (de) *	1999-09-28	2005-05-12	Otsuka Pharmaceutical Factory, Inc., Naruto	Triazolpurin-derivate, medikamentzusammensetzungen, die diese enthalten und mittel, die affinität zum adenosin a3 rezeptor zeigen
US7160890B2 (en) *	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
NZ525885A (en) *	2000-12-01	2005-01-28	Osi Pharm Inc	Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities
EP1390349B1 (en) *	2001-05-31	2012-07-25	Sanofi	Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
HUP0105406A3 (en) *	2001-12-21	2003-12-29	Sanofi Aventis	Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105407A3 (en) *	2001-12-21	2004-04-28	Sanofi Aventis	Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en)	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

2002
- 2002-11-15 HU HU0203976A patent/HUP0203976A3/hu unknown
2003
- 2003-11-11 RS YUP-2005/0364A patent/RS51320B/sr unknown
- 2003-11-11 UA UAA200505875A patent/UA78889C2/uk unknown
- 2003-11-11 DE DE60305058T patent/DE60305058T2/de not_active Expired - Lifetime
- 2003-11-11 KR KR1020057008683A patent/KR20050088291A/ko active IP Right Grant
- 2003-11-11 CN CNB2003801062293A patent/CN1332960C/zh not_active Expired - Fee Related
- 2003-11-11 NZ NZ540029A patent/NZ540029A/en not_active IP Right Cessation
- 2003-11-11 DK DK03773882T patent/DK1560828T3/da active
- 2003-11-11 PT PT03773882T patent/PT1560828E/pt unknown
- 2003-11-11 WO PCT/HU2003/000095 patent/WO2004046146A1/en active IP Right Grant
- 2003-11-11 ES ES03773882T patent/ES2263039T3/es not_active Expired - Lifetime
- 2003-11-11 SI SI200330299T patent/SI1560828T1/sl unknown
- 2003-11-11 ME MEP-190/08A patent/MEP19008A/xx unknown
- 2003-11-11 PL PL376837A patent/PL376837A1/pl not_active Application Discontinuation
- 2003-11-11 CA CA2505910A patent/CA2505910C/en not_active Expired - Fee Related
- 2003-11-11 EP EP03773882A patent/EP1560828B9/en not_active Expired - Lifetime
- 2003-11-11 BR BR0316355-5A patent/BR0316355A/pt not_active IP Right Cessation
- 2003-11-11 MX MXPA05005198A patent/MXPA05005198A/es active IP Right Grant
- 2003-11-11 JP JP2004552920A patent/JP4533148B2/ja not_active Expired - Fee Related
- 2003-11-11 EA EA200500830A patent/EA007595B1/ru unknown
- 2003-11-11 AU AU2003282263A patent/AU2003282263B2/en not_active Ceased
- 2003-11-11 AT AT03773882T patent/ATE325123T1/de active
- 2003-11-14 TW TW092131901A patent/TWI248934B/zh not_active IP Right Cessation
- 2003-11-14 AR ARP030104200A patent/AR041968A1/es unknown
2005
- 2005-05-10 IL IL168516A patent/IL168516A/en not_active IP Right Cessation
- 2005-05-10 TN TNP2005000133A patent/TNSN05133A1/en unknown
- 2005-05-11 ZA ZA200503807A patent/ZA200503807B/en unknown
- 2005-05-16 US US11/130,429 patent/US7419977B2/en not_active Expired - Fee Related
- 2005-05-31 IS IS7874A patent/IS2456B/is unknown
- 2005-06-13 NO NO20052866A patent/NO20052866D0/no not_active Application Discontinuation
- 2005-06-13 MA MA28334A patent/MA27501A1/fr unknown
- 2005-06-14 HR HR20050540A patent/HRP20050540A2/xx not_active Application Discontinuation
- 2005-06-14 CO CO05057645A patent/CO5690577A2/es not_active Application Discontinuation
- 2005-11-07 HK HK05109885A patent/HK1077819A1/xx not_active IP Right Cessation
2006
- 2006-07-28 CY CY20061101054T patent/CY1105180T1/el unknown
2008
- 2008-06-17 US US12/140,512 patent/US7709489B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HK1077819A1 (en)	2006-02-24
EP1560828B1 (en)	2006-05-03
DE60305058T2 (de)	2006-12-14
TNSN05133A1 (en)	2007-05-14
AU2003282263B2 (en)	2009-05-14
DK1560828T3 (da)	2006-09-04
HU0203976D0 (en)	2003-01-28
KR20050088291A (ko)	2005-09-05
CA2505910A1 (en)	2004-06-03
IS7874A (is)	2005-05-31
EA200500830A1 (ru)	2005-10-27
EA007595B1 (ru)	2006-12-29
CY1105180T1 (el)	2010-03-03
IL168516A (en)	2011-05-31
AU2003282263A1 (en)	2004-06-15
PT1560828E (pt)	2006-08-31
ATE325123T1 (de)	2006-06-15
EP1560828B9 (en)	2007-02-14
BR0316355A (pt)	2005-09-27
HRP20050540A2 (en)	2005-08-31
NZ540029A (en)	2007-01-26
NO20052866L (no)	2005-06-13
HUP0203976A2 (hu)	2004-07-28
UA78889C2 (en)	2007-04-25
CN1332960C (zh)	2007-08-22
HUP0203976A3 (en)	2004-08-30
ZA200503807B (en)	2006-08-30
DE60305058D1 (de)	2006-06-08
US20050234056A1 (en)	2005-10-20
NO20052866D0 (no)	2005-06-13
MA27501A1 (fr)	2005-08-01
IS2456B (is)	2008-11-15
US7709489B2 (en)	2010-05-04
WO2004046146A1 (en)	2004-06-03
SI1560828T1 (sl)	2006-08-31
US20080255110A1 (en)	2008-10-16
JP2006515572A (ja)	2006-06-01
RS20050364A (en)	2007-08-03
TW200413369A (en)	2004-08-01
ES2263039T3 (es)	2006-12-01
US7419977B2 (en)	2008-09-02
CN1726213A (zh)	2006-01-25
MXPA05005198A (es)	2005-08-18
EP1560828A1 (en)	2005-08-10
PL376837A1 (pl)	2006-01-09
JP4533148B2 (ja)	2010-09-01
TWI248934B (en)	2006-02-11
MEP19008A (en)	2010-06-10
CA2505910C (en)	2010-07-13
AR041968A1 (es)	2005-06-01
CO5690577A2 (es)	2006-10-31

Publication	Publication Date	Title
RS51320B (sr)	2010-12-31	Derivati imidazohinolina kao veznici a3 receptora adenozina
ME00411B (me)	2011-10-10	Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavistan od natrijuma
HRP20031098B1 (en)	2012-03-31	Beta-amino tetrahydroimidazo (1,2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
RS52261B (sr)	2012-10-31	Amidofenoksi indazoli kao korisni inhibitori c-met-a
RS50519B (sr)	2010-05-07	Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona
RS52953B (sr)	2014-02-28	Piridopirimidinonski inhibitori pi3 kalfa
RS54702B1 (sr)	2016-08-31	Pirazolohinolinski derivati kao inhibitori pde9
MEP8409A (en)	2011-12-20	Fused heterocyclic compound
RS50045B (sr)	2008-11-28	Aktivatori glukokinaze
BR0316241A (pt)	2005-10-04	Pirrolobenzodiazepinas
WO2007016392A3 (en)	2007-05-24	Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AR036093A1 (es)	2004-08-11	Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios
HRP20070529T3 (en)	2008-05-31	Imidazole derivatives as glutmate receptor antagonists
HRP20040429B1 (en)	2007-10-31	Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
RS51949B (sr)	2012-02-29	Inhibitori kinaze
RS54775B1 (sr)	2016-10-31	Nova disupstituisana jedinjenja 3,4-diamino-3-ciklobuten-1,2-diona za lečenje bolesti u kojima posreduju hemokini
DK1485377T3 (da)	2010-04-19	Pyranoner egnede som ATM-inhibitorer
RS53389B (sr)	2014-10-31	Farmaceutska jedinjenja
HRP20031091B1 (en)	2012-05-31	Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
DK1204662T3 (da)	2004-10-04	Azaindoler med serotoninreceptoraffinitet
TW200510320A (en)	2005-03-16	Aminoquinoline derivatives and their use as adenosine A3 ligands
ATE276257T1 (de)	2004-10-15	Pyrazinonderivate
ATE525366T1 (de)	2011-10-15	Benzoxazolderivate und pharmazeutische zubereitungen die diese enthalten
ATE550332T1 (de)	2012-04-15	4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
HUP0303457A2 (hu)	2004-01-28	Antimikrobiális hatású 2-piridonok, ezeket tartalmazó készítmények és alkalmazásuk